Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES (ABT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company usually posts poor financials for mid or long term investments.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The company returns high margins, thereby supporting business profitability.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The stock is in a well-established, long-term rising trend above the technical support level at 55.47 USD
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 63.6.
  • Technically, the stock approaches a strong medium-term resistance at USD 63.62.
  • The group usually releases earnings worse than estimated.
  • The company's enterprise value to sales, at 4.02 times its current sales, is high.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.86 times its estimated earnings per share for the ongoing year.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ABBOTT LABORATORIES9.53%109 346
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708
MERCK AND COMPANY5.01%158 970
AMGEN2.33%117 942
BAYER0.35%102 690
GLAXOSMITHKLINE12.98%98 990
SANOFI-8.45%95 715
ASTRAZENECA5.99%92 832
NOVO NORDISK A/S-8.94%91 116
ELI LILLY AND COMPANY-2.07%89 841
BRISTOL-MYERS SQUIBB COMPAN..-14.02%86 255
CELGENE CORPORATION-23.78%55 529
ALLERGAN PLC-6.06%52 216
More Results
Financials ($)
Sales 2018 30 950 M
EBIT 2018 6 458 M
Net income 2018 2 536 M
Debt 2018 15 152 M
Yield 2018 1,79%
P/E ratio 2018 47,86
P/E ratio 2019 33,96
EV / Sales 2018 4,02x
EV / Sales 2019 3,71x
Capitalization 109 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ABBOTT LABORATORIES
Duration : Period : Day
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Duration : Period : Week
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders